{"generic":"Tesamorelin Acetate","drugs":["Egrifta","Tesamorelin Acetate"],"mono":{"0":{"id":"929756-s-0","title":"Generic Names","mono":"Tesamorelin Acetate"},"1":{"id":"929756-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929756-s-1-4","title":"Adult Dosing","mono":"<b>Lipodystrophy associated with Human immunodeficiency virus infection:<\/b> 2 mg SUBQ once daily in the abdomen; rotate abdominal injection sites "},"1":{"id":"929756-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in children "},"3":{"id":"929756-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Lipodystrophy associated with Human immunodeficiency virus infection<br\/>"}}},"3":{"id":"929756-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929756-s-3-9","title":"Contraindications","mono":"<ul><li>disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor\/surgery, or head irradiation or trauma<\/li><li>hypersensitivity to tesamorelin and\/or mannitol<\/li><li>malignancy, active (either newly diagnosed or recurrent); malignancies should be inactive and completely treated prior to initiating therapy<\/li><li>pregnancy; may cause fetal harm<\/li><\/ul>"},{"id":"929756-s-3-10","title":"Precautions","mono":"<ul><li>acute respiratory failure or acute critical illness (due to complications following multiple accidental trauma or open-heart or abdominal surgery); increased risk of mortality following growth hormone therapy<\/li><li>children with open epiphyses; risk of linear growth acceleration and excessive growth<\/li><li>diabetes; risk of new or worsening retinopathy due to increases in insulin-like growth factor 1; monitoring recommended<\/li><li>glucose intolerance may occur; monitoring recommended<\/li><li>hypersensitivity reactions (eg, pruritus, erythema, flushing, urticaria, and other rash) have been reported<\/li><li>insulin-like growth factor 1 (IGF-1) elevations have been reported, some within 13 weeks of treatment; monitoring recommended; consider discontinuing therapy for persistent elevations (eg, greater than 3 standard deviation scores)<\/li><li>malignancy, history of treated and stable; risk of reactivation of underlying malignancy due to induction of endogenous growth hormone<\/li><li>nonmalignant neoplasms, history; induction of endogenous growth hormone may increase the risk of neoplasm<\/li><li>report suspected adverse reactions to EMD Serono at 1-800-283-8088 ext. 5563 or to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929756-s-3-11","title":"Pregnancy Category","mono":"Tesamorelin: X (FDA)<br\/>"},{"id":"929756-s-3-12","title":"Breast Feeding","mono":"Tesamorelin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929756-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (2% to 6.1%)<\/li><li><b>Dermatologic:<\/b>Erythema at injection site (1.2% to 8.5%), Injection site irritation (2.9%), Injection site pain (4.1%), Injection site pruritus (2% to 7.6%), Injection site reaction (1.3% to 24.5%)<\/li><li><b>Endocrine metabolic:<\/b>Serum insulin-like growth factor 1 measurement, elevated (33.7% to 47.4%)<\/li><li><b>Immunologic:<\/b>Antibody development (47.4% to 49.5%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (13.3%), Pain, Extremity (3.3% to 6.1%)<\/li><li><b>Neurologic:<\/b>Carpal tunnel syndrome (1.5%)<\/li><\/ul>"},"6":{"id":"929756-s-6","title":"Drug Name Info","sub":{"0":{"id":"929756-s-6-17","title":"US Trade Names","mono":"Egrifta<br\/>"},"2":{"id":"929756-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Growth Hormone Releasing Hormone Analog<\/li><\/ul>"},"3":{"id":"929756-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"929756-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"929756-s-7","title":"Mechanism Of Action","mono":"Tesamorelin acetate, an analog of human growth hormone (GH)-releasing factor, stimulates GH secretion which increases insulin-like growthfactor-I (IGF-I) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels.<br\/>"},"8":{"id":"929756-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"929756-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, SubQ: 0.15 hour<\/li><li>Bioavailability, SubQ: less than 4%<\/li><\/ul>"},"1":{"id":"929756-s-8-24","title":"Distribution","mono":"<ul><li>Vd, healthy subjects: 9.4 L\/kg<\/li><li>Vd, HIV-infected patients: 10.5 L\/kg<\/li><\/ul>"},"4":{"id":"929756-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Healthy subjects, 26 minutes<\/li><li>HIV-infected patients, 38 minutes<\/li><\/ul>"}}},"9":{"id":"929756-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Add 2.2 mL of the supplied diluent to the contents of the first 1-mg vial; reconstitute by rolling between hands for 30 seconds; do not shake.<\/li><li>Add the contents of the reconstituted first vial to a second 1-mg vial; reconstitute by rolling between hands for 30 seconds; do not shake; use immediately.<\/li><li>Do not freeze or refrigerate the reconstituted solution; if not used immediately, discard the reconstituted solution.<\/li><li>Recommended injection site is the abdomen; rotate injection sites; avoid injecting into scar tissue, bruises, or the navel.<\/li><\/ul>"},"10":{"id":"929756-s-10","title":"Monitoring","mono":"<ul><li>reduction in visceral adipose tissue by waist circumference or CT scan measurement is indicative of efficacy<\/li><li>insulin-like growth factor-1 levels; during therapy<\/li><li>glucose metabolism changes; periodically in all patients<\/li><li>retinopathy, new-onset or worsening of; regularly in patients with diabetes<\/li><\/ul>"},"11":{"id":"929756-s-11","title":"How Supplied","mono":"<b>Egrifta<\/b><br\/>Subcutaneous Powder for Solution: 2 MG<br\/>"},"13":{"id":"929756-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause arthralgia, myalgia, fluid retention, injection site reactions (eg, erythema, pruritus, pain, irritation, and bruising), and alteration in glucose tolerance.<\/li><li>Advise patients with diabetes to report new-onset or worsening retinopathy.<\/li><li>Instruct patient to immediately report signs\/symptoms of hypersensitivity (eg, pruritus, erythema, flushing, urticaria, or other rash).<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}